# **Resource Summary Report**

Generated by dkNET on May 21, 2025

# Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis - Unresponsive Populations

RRID:SCR\_004019

Type: Tool

# **Proper Citation**

Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis - Unresponsive Populations (RRID:SCR\_004019)

#### Resource Information

**URL:** http://clinicaltrials.gov/show/NCT01211678

**Proper Citation:** Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis - Unresponsive Populations (RRID:SCR\_004019)

**Description:** A consortium evaluating a new biomarker screening test that might help identify patients with rheumatoid arthritis (RA) who are unlikely to benefit from anti-tumor necrosis factor-alpha (TNFalpha) medications. BATTER-UP will enroll around 1,000 patients being treated by one of several marketed anti-TNF RA drugs: Enbrel, Remicade, Humira, Simponi, or Cimzia. Through data analyses and predictive response modeling, the consortium aims to better understand which patients with RA will derive the greatest benefit from TNF inhibitors. The investigators in this observational study will attempt to validate an 8gene biomarker set based on work by Biogen Idec researchers as likely to predict anti-TNF responsiveness in patients with RA. In preliminary results, the 8-gene biomarker set predicted with 89% accuracy individuals who did not reach European League Against Rheumatism (EULAR) Disease Activity Score (DAS)-28 good response after 14 weeks of treatment. The 8 genes included in the screen are CLTB, MXRA7, CXorf52, COL4A3BP, YIPF6, FAM44A, SFRS2, and PGK1. Biological samples and clinical outcome information will be used to confirm and extend the utility of previously published biomarkers that can predict response to anti-TNF agents. These data may also generate new hypotheses for further testing. The BATTER-UP samples and data will be established as a reference set for investigation of personalized medicine in RA. The study will be a resource of DNA and other biological materials that can be investigated for biomarkers in the future as new technologies arise.

**Abbreviations: BATTER-UP** 

**Synonyms:** Biomarkers of Anti-TNF-alpha Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients, Biomarkers of Anti-TNF- Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients (BATTER-UP), Biomarkers of Anti-TNF- Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients

Resource Type: portal, topical portal, data or information resource

**Keywords:** anti-tumor necrosis factor-alpha, gene, biomarker, drug development, basic research, personalized medicine, enbrel, remicade, humira, simponi, cimzia, cltb, mxra7, cxorf52, col4a3bp, yipf6, fam44a, sfrs2, pgk1, clinical, dna, serum, plasma, rna, whole blood

Funding: Biogen Idec; Bristol-Myers Squibb;

Centocor;

Crescendo Bioscience:

Genentech;

Medco Health Solutions;

Regeneron Pharmaceuticals;

Sanofi-Aventis

Resource Name: Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis -

**Unresponsive Populations** 

Resource ID: SCR\_004019

Alternate IDs: nlx 158440

Record Creation Time: 20220129T080222+0000

Record Last Update: 20250519T203319+0000

## Ratings and Alerts

No rating or validation information has been found for Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis - Unresponsive Populations.

No alerts have been found for Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis - Unresponsive Populations.

### **Data and Source Information**

Source: SciCrunch Registry

# **Usage and Citation Metrics**

We have not found any literature mentions for this resource.